Skip to main content

PHASE II STUDY OF SINGLE AGENT CLOFARABINE IN PREVIOUSLY UNTREATED OLDER ADULT PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML) UNLIKELY TO BENEFIT FROM STANDARD INDUCTION CHEMOTHERAPY

Publication ,  Conference
Erba, H; Kantarjian, H; Claxton, D; Arellano, M; Lyons, R; Kovacsovics, T; Gabrilove, J; Eckert, S; Abichandani, R; Faderl, S
Published in: HAEMATOLOGICA
June 27, 2008

Duke Scholars

Published In

HAEMATOLOGICA

ISSN

0390-6078

Publication Date

June 27, 2008

Volume

93

Start / End Page

354 / 354

Publisher

FERRATA STORTI FOUNDATION

Related Subject Headings

  • Immunology
  • 3201 Cardiovascular medicine and haematology
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Erba, H., Kantarjian, H., Claxton, D., Arellano, M., Lyons, R., Kovacsovics, T., … Faderl, S. (2008). PHASE II STUDY OF SINGLE AGENT CLOFARABINE IN PREVIOUSLY UNTREATED OLDER ADULT PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML) UNLIKELY TO BENEFIT FROM STANDARD INDUCTION CHEMOTHERAPY. In HAEMATOLOGICA (Vol. 93, pp. 354–354). FERRATA STORTI FOUNDATION.
Erba, H., H. Kantarjian, D. Claxton, M. Arellano, R. Lyons, T. Kovacsovics, J. Gabrilove, S. Eckert, R. Abichandani, and S. Faderl. “PHASE II STUDY OF SINGLE AGENT CLOFARABINE IN PREVIOUSLY UNTREATED OLDER ADULT PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML) UNLIKELY TO BENEFIT FROM STANDARD INDUCTION CHEMOTHERAPY.” In HAEMATOLOGICA, 93:354–354. FERRATA STORTI FOUNDATION, 2008.
Erba H, Kantarjian H, Claxton D, Arellano M, Lyons R, Kovacsovics T, et al. PHASE II STUDY OF SINGLE AGENT CLOFARABINE IN PREVIOUSLY UNTREATED OLDER ADULT PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML) UNLIKELY TO BENEFIT FROM STANDARD INDUCTION CHEMOTHERAPY. In: HAEMATOLOGICA. FERRATA STORTI FOUNDATION; 2008. p. 354–354.
Erba H, Kantarjian H, Claxton D, Arellano M, Lyons R, Kovacsovics T, Gabrilove J, Eckert S, Abichandani R, Faderl S. PHASE II STUDY OF SINGLE AGENT CLOFARABINE IN PREVIOUSLY UNTREATED OLDER ADULT PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML) UNLIKELY TO BENEFIT FROM STANDARD INDUCTION CHEMOTHERAPY. HAEMATOLOGICA. FERRATA STORTI FOUNDATION; 2008. p. 354–354.

Published In

HAEMATOLOGICA

ISSN

0390-6078

Publication Date

June 27, 2008

Volume

93

Start / End Page

354 / 354

Publisher

FERRATA STORTI FOUNDATION

Related Subject Headings

  • Immunology
  • 3201 Cardiovascular medicine and haematology
  • 1102 Cardiorespiratory Medicine and Haematology